Insulin Dégludec; a new long-acting insulinDiabetes mellitus is a disease process that is increasingly common and increasing in prevalence and affects many people. Adequate treatment, management and ultimately control of diabetes is a complex and difficult task. Many factors contribute to the complexity of diabetes treatment. These factors play a role in the high frequency of non-compliance with therapeutic treatments for diabetes. Identifying, understanding, and ultimately resolving these issues will help alleviate these barriers in diabetes management. Factors contributing to non-adherence to insulin therapy According to Stockley (2014), consistently following an insulin therapy program will better control blood sugar levels, decrease and help prevent future incidences of diabetes-related health problems. However, there are many reasons why these therapies are not systematically followed. These reasons for non-compliance with insulin treatment regimens include: fear of hypoglycemia, and more particularly nocturnal hypoglycemia, both on the part of patients and the doctors who treat them, difficulty of the device injection, injection pain and the complexity of insulin dosages (Stockley, 2014). Long-acting insulin The use of long-acting insulin (long-acting insulin) is a common and conventional treatment for type 1 diabetes and type 2 diabetes. In type 1 diabetes, long-acting insulins are used with meals as a subcutaneous injection. Long-acting insulin can also be combined with oral antidiabetic hypoglycemic medications, as is the case for type 2 diabetes. The two current and generally long-acting insulins are: insulin glargine and insulin determir. . These types of insulin are called long-acting insulin and so called because of the slow, prolonged abs...... middle of paper ......n other long-acting insulins are patients who experience insulin variability (Stockley, 2014, p. This variability results in some individuals from the dramatic peak in the therapeutic effect of current long-acting insulins. The final group of diabetic patients who would benefit from insulin degludec would be those having difficulty following current strict insulin dosing schedules (Stockley, 2014, p. 19). Conclusion The ultimate goal of diabetes management is the control and stabilization of blood glucose levels. Continuous glucose monitoring reduces a patient's risk of developing diabetes-related health problems in the future. By reducing or even eliminating barriers that prevent patients from following prescribed insulin treatments, adherence can be increased. patients and improve their overall health..